Does Wegovy cause sensitive or reactive skin?

You've noticed your skin feeling different since starting Wegovy, here's what that usually means

Picture this: a few weeks into treatment, you find that the skin around your injection site stays pink and tender for longer than you expected, or the skin on your arms feels dry and a little raw. This is a reasonable thing to notice, and you are not imagining it.

The most well-documented skin effect of semaglutide is a localised injection-site reaction. According to the NHS medicines information for semaglutide, these can include redness, bruising, itching, pain or mild swelling at the spot where you injected. They tend to settle within a day or two, and rotating your injection site (between the abdomen, thigh and upper arm) reduces how often they happen.

Skin sensitivity that feels more general is less straightforward. Semaglutide slows gastric emptying and reduces calorie intake significantly; as body composition shifts, some people find their skin becomes temporarily drier or more reactive to products they have used for years. This is more likely a consequence of rapid physiological change than a direct drug effect. Staying well-hydrated and maintaining protein intake matters here, your prescriber or a dietitian can advise on what to prioritise during treatment. If you want to understand the range of ways Wegovy can affect the skin specifically, our dedicated guide to Wegovy's effects on skin covers both localised and more general responses in one place. For a broader picture of how the body responds to this medicine, the full Wegovy side-effects overview covers the range from common to rare in more detail.

A quick habit worth building: before each injection, run your finger gently over the intended site. If the skin there is already sore, bruised or irritated, move to a different area. It takes under a minute and meaningfully reduces the chance of a cumulative local reaction.

Skin reactions that go beyond the injection site, what the SmPC says

The Wegovy SmPC, accessible via the Electronic Medicines Compendium, lists uncommon and rare skin-related adverse effects separately from localised injection reactions. Pruritus (generalised itching) is listed as uncommon, affecting fewer than 1 in 100 people. Alopecia (hair thinning or shedding) has been reported in clinical experience, typically in the context of rapid weight loss rather than as a direct pharmacological effect of semaglutide, and usually resolves as the body stabilises.

Rash, urticaria (hives) and angioedema are listed as potential hypersensitivity responses. These deserve more attention than a local injection-site blush: a spreading rash, significant swelling, or difficulty breathing are signs of a serious allergic reaction and require urgent medical help. Stop the injection and call 999 or go to A&E if you experience those symptoms together.

There is also a small population of people for whom semaglutide appears to worsen existing inflammatory skin conditions, though robust clinical data in this group are limited. If you have eczema, psoriasis or rosacea that flares after starting treatment, raise it with your prescriber rather than managing it independently, they may adjust the titration schedule or review whether continuing is appropriate. The detailed page on semaglutide and skin sensitivity explores these less common presentations further.

When skin changes need medical attention, and when to use Yellow Card

Most injection-site reactions are an inconvenience rather than a danger. The ones that warrant a call to your prescriber are: a reaction that worsens over several days rather than fading, any sign of infection at the site (increasing warmth, pus, fever), or skin changes that appear elsewhere on the body and seem to track with dose increases.

Seek urgent help (same day, via 111 or your GP) for a rash that spreads quickly, swelling of the lips, tongue or throat, or any allergic symptom alongside difficulty breathing. These are uncommon but are listed hypersensitivity reactions in the prescribing information.

The MHRA's Yellow Card reporting tool exists for exactly this situation: if you experience a skin reaction you did not expect, reporting it contributes to the ongoing post-market safety monitoring that applies to all Black Triangle medicines, including Wegovy. You do not need to be certain it is drug-related, a suspicion is enough to report.

If you are considering starting treatment and have a history of sensitive or reactive skin, the consultation is the place to discuss it. At nume, a named prescriber reviews your full picture before any prescription is issued, they can weigh up your skin history alongside other health factors and advise on what to watch for during the titration period. You can explore starting that process via our free consultation page.

Skin sensitivity in context: what Wegovy does and doesn't do

It is worth being clear about what the clinical evidence does not show. Wegovy is not associated with widespread skin thinning, photosensitivity, or any dermatological effect comparable to, say, long-term corticosteroid use. The trial programme for semaglutide 2.4mg involved thousands of adults, and the skin-related adverse event profile was dominated by localised injection reactions, not systemic skin changes.

The beneficial changes some people report on Wegovy occasionally include improved skin clarity, plausibly connected to improved metabolic health and reduced inflammation, though this is anecdotal rather than a licensed claim. Weight loss itself is associated with reduced systemic inflammation over time, which can have secondary skin benefits for people whose skin reactivity was tied to metabolic factors.

For a full comparison of the skin-specific effects reported across the semaglutide clinical programme, the evidence on semaglutide and skin covers that ground in depth. And if you are trying to weigh Wegovy's overall side-effect profile before deciding, the complete side-effect breakdown is a useful next read. These are prescription medicines; suitability is a clinical judgement. Our prescribers discuss side effects as a standard part of every consultation, check your eligibility and start that conversation at nume.co.uk/pages/weight-loss-treatments.